Introduction {#Sec1}
============

The progression of Alzheimer's disease (AD) to moderate and severe stages is associated with increasing cognitive and functional decline, greater dependence and burden on caregivers, and higher direct and indirect costs, even in non-institutionalized patients \[[@CR1]--[@CR4]\]. In addition, the challenges faced by community-dwelling patients with AD and their caregivers are often aggravated by poor medication adherence \[[@CR5]--[@CR7]\].

Memantine is an uncompetitive antagonist of *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptors, approved in the USA and many countries worldwide for the treatment of moderate to severe AD \[[@CR8]--[@CR10]\]. In the USA, it is currently administered twice daily as an immediate-release formulation, with a maximum recommended dosage of 20 mg/day. Considering the problems associated with poor medication adherence in AD, the availability of an extended-release, once-daily memantine formulation would be expected to provide improved convenience, and may potentially enable an increased daily dosage without affecting the drug's favorable safety and tolerability profile \[[@CR11], [@CR12]\].

The objective of this study was to evaluate the efficacy, safety, and tolerability of a novel, higher-dose (28-mg), once-daily, extended-release memantine formulation in outpatients with moderate-to-severe AD. Stable use of any cholinesterase inhibitor was required in this study, similar to a previous trial of immediate-release memantine (10 mg, twice daily) in patients with moderate-to-severe AD who were taking the cholinesterase inhibitor donepezil \[[@CR9]\]. In addition, the majority of participants in this study were primarily of Hispanic origin (68.9 %), including participants from Argentina, Mexico, and Chile, a patient population that has traditionally been under-represented in trials of memantine and other AD drugs \[[@CR13]\].

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Study participants were community-dwelling men and women of at least 50 years of age, with a clinical diagnosis of probable AD using Diagnostic and Statistical Manual of Mental Disorders-Text Revision (DSM-IV-TR) \[[@CR14]\] and National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association (NINCDS--ADRDA) \[[@CR15]\] criteria, a Mini-Mental State Examination (MMSE) score \[[@CR16]\] in the 3--14 range at screening and baseline, and results of a magnetic resonance imaging (MRI) or computed tomography (CT) scan (within the past 12 months) consistent with this diagnosis. At screening, all participants were required to be receiving ongoing cholinesterase inhibitor therapy (stable dosage for at least 3 months) and to have normal (or clinically non-significant) results on physical examination, laboratory evaluations, and electrocardiogram (ECG).

Individuals were excluded from the study if, by the judgment of the investigator, they had any of the following (see Electronic Supplementary Material for a full list of inclusion and exclusion criteria): clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease or cancer; a neurologic disorder or dementia complicated by other organic disease or predominant delusions; any DSM-IV Axis I disorder other than AD; evidence of clinically significant disease involving the central nervous system; systolic hypertension or hypotension; a modified Hachinski Ischemia Score of \>4 at screening; and current or prior exposure to any unapproved concomitant medication that could not be discontinued or switched to an allowable alternative medication before baseline.

Written informed consent was provided by the patient's caregiver and either the patient (if possible) or a legally acceptable representative. The study was designed to comply with the International Conference on Harmonization (ICH) guidance on General Considerations for Clinical Trials (62 FR 6611, December 17, 1997), Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (62 FR 62922, November 25, 1997), and Good Clinical Practice: Consolidated Guidance (62 FR 25692, May 9, 1997). The protocol was reviewed and approved in the USA by an institutional review board for each site, and by both an ethics committee and a Ministry of Health agency within each of the other countries.

Trial Design {#Sec4}
------------

This study (MEM-MD-50; NCT00322153; <http://clinicaltrials.gov/show/NCT00322153>) was a multinational, randomized, double-blind, placebo-controlled, parallel-group clinical trial in which participants were required to complete between 4 and 14 days of single-blind placebo treatment prior to baseline. At baseline, each patient was randomized (1:1) to receive placebo or extended-release memantine. The Statistical Programming department at Forest Research Institute generated (using SAS, v. 9.1.3; SAS Institute Inc., Cary, NC, USA) and maintained a list of randomization codes in a secure area. At baseline, each patient was sequentially assigned a randomization number corresponding to treatment assignment. Medication corresponding to the randomization numbers was provided to each study site by Forest Laboratories. Patients assigned to memantine initially received 7 mg/day (once daily), and were up-titrated weekly in 7 mg/day increments, reaching the target dose of 28 mg at the beginning of week 4. By week 8, patients were required to tolerate a minimum of 21 mg/day, or they were to be discontinued from the trial. Study drug and placebo were administered in identically appearing blister packs, either in the morning or evening, and the dosing time remained consistent throughout the study. Each blister pack contained a two-part, three-panel label; the first remained on the pack, and the second and third were placed in the case report form. The third panel was sealed and contained the identity of the treatment in the event of an emergency; no treatment assignment was unblinded by this procedure or by any other procedure prior to database lock. All study sites underwent pre-study site feasibility and had to provide information to ensure that the overall education, experience, and training of study personnel were adequate to conduct clinical trials according to good clinical practice, and that the investigators were qualified and trained in both the treatment of AD and clinical research. Investigators and relevant site personnel were trained at an investigator meeting prior to the initiation of the study, which included a protocol overview and a review of study procedures, outcome measures, investigator responsibility, and recruitment. Outcome measures were administered by trained and skilled individuals during the trial.

Efficacy Parameters {#Sec5}
-------------------

The two co-primary efficacy parameters were baseline-to-endpoint change on the Severe Impairment Battery (SIB) total score \[week 24, last-observation-carried-forward (LOCF) approach\] and the endpoint rating on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) scale (week 24, LOCF). The SIB is a 40-item, 100-point scale, used to evaluate cognition in patients with advanced dementia; lower scores indicate greater impairment \[[@CR17]\]. The CIBIC-Plus is a 7-point scale used to assess the global clinical status of a patient, with scores ranging from 1 (marked improvement) to 7 (marked worsening); raters are blinded to data from other post-baseline rating instruments and safety measures and do not have access to prior post-baseline CIBIC-Plus ratings \[[@CR18]\]. The secondary efficacy parameter was the change on the 19-item Alzheimer's Disease Cooperative Study--Activities of Daily Living (ADCS--ADL~19~) scale, a 54-point instrument used to evaluate functional abilities in patients with moderate to severe AD; lower scores indicate greater impairment \[[@CR19], [@CR20]\]. Additional parameters included changes on the Neuropsychiatric Inventory (NPI), a 12-item, 144-point scale used to measure the frequency and severity of behavioral disturbances in patients with dementia (higher scores indicate greater impairment), \[[@CR21]\] and the semantic verbal fluency test (VFT), in which patients were assessed on the basis of the number of animals they could name in 60 s \[[@CR22]\]. All assessment scales were administered at baseline and at the end of weeks 4, 8, 12, 18, and 24, except the NPI, which was administered at weeks 8, 12, 18, and 24. The NPI caregiver distress rating, as well as two exploratory health outcomes measures (the Modified Resource Utilization in Dementia-Lite and the Caregiver Perceived Burden Questionnaire) were also administered in this study but were not analyzed for this report.

Measures of safety and tolerability included physical examinations, measurements of vital signs, laboratory tests (hematology, blood chemistry, and urinalysis), ECGs, and recordings of adverse events. Blood and urine samples were collected and ECGs were taken at screening and week 24; adverse events and vital signs were recorded at baseline and at each post-baseline visit. Any clinical findings discovered during the final examination, or at premature discontinuation, were followed until the condition returned to pre-study status or could be explained as being unrelated to the study drug. A follow-up visit could be scheduled within 30 days of termination, as needed.

Adverse events were solicited from patients and caregivers at all study visits (and during any contact with a patient or patient representative occurring outside of a defined study visit, including any contact up to 30 days after study completion), using non-leading questions such as "How do you feel?" Adverse events were coded according to the *Medical Dictionary for Regulatory Activities* (version 7.0 or newer), and an assessment of the severity, chronicity, causal relationship to study medication, and seriousness of the event was provided by an investigator. An adverse event was considered to be treatment emergent if it was not present prior to the first dose of double-blind study medication, or if it increased in severity following the dosing. Patients who experienced more than one adverse event within a specific category were counted only once.

Statistical Analysis {#Sec6}
--------------------

The study sample size was calculated on the basis of week 24 (LOCF) effect sizes (0.40 for SIB; 0.24 for CIBIC-Plus) established in a previous study of memantine (10 mg/day, twice daily) in patients with moderate to severe AD who were receiving stable, concomitant donepezil treatment \[[@CR9]\]. Assuming that these effect sizes are the true treatment effects for extended-release memantine, a sample size of 300 patients per group was needed to provide a power of at least 83 % to detect these effect sizes (or greater) simultaneously at a significance level of 0.05 (two-sided).

The safety population consisted of all randomized patients who received at least one dose of double-blind study medication. The intent-to-treat (ITT) population consisted of all patients from the safety population who completed at least one post-baseline primary efficacy assessment (SIB or CIBIC-Plus). Primary efficacy analyses were based on the ITT population and the LOCF approach for imputation of missing values. The changes from baseline to week 24 (LOCF) in SIB scores were analyzed (by Forest Research Institute) by means of a two-way analysis of covariance (ANCOVA) model, with treatment group and study center as factors and baseline as a covariate; the week 24 (LOCF) CIBIC-Plus scores were analyzed using a Cochran--Mantel--Haenszel test with modified ridit scores, controlling for study center. Secondary (ADCS--ADL~19~) and additional efficacy parameters (NPI, VFT) were analyzed using the ANCOVA model. Additional analyses for all outcomes included the use of observed cases (OC) in the same models. For the two co-primary parameters, a sensitivity analysis using a mixed-effects model for repeated measures (MMRM) based on OC data was also performed, using treatment, visit, and treatment-by-visit interaction as factors and baseline score (SIB or Clinician's Interview-Based Impression of Severity) as a covariate. For all statistical analyses, the significance level was 0.05 (two-sided). No interim analyses were planned or performed.

The number and percentage of patients with treatment-emergent adverse events in each treatment group were tabulated by system organ class, preferred term, severity, and relationship to the study drug. The number and percentage of patients with any treatment-emergent adverse events, serious adverse events, and adverse events leading to premature discontinuations were presented by treatment group, system organ class, and preferred term.

Results {#Sec7}
=======

The study was conducted at 83 medical research centers in four countries (Argentina: 23 centers, 311 patients; USA: 38 centers, 179 patients; Mexico: 11 centers, 97 patients; Chile: 11 centers, 90 patients), between June 2005 and October 2007.

A total of 677 participants were randomized (1:1) to receive either placebo (*n* = 335) or extended-release memantine (*n* = 342), with 272 (81.2 %) and 273 (79.8 %) participants completing the trial, respectively (Fig. [1](#Fig1){ref-type="fig"}). By the end of the study, the mean daily dose of extended-release memantine was 27.0 mg, with a total of 314 patients (92.1 %) receiving the maximum daily dose of 28 mg. The treatment groups were well matched for demographic and clinical characteristics at baseline (Table [1](#Tab1){ref-type="table"}). All participants were in the range of moderate-to-severe AD (MMSE range of 3--14 at screening and 3--17 at baseline; mean Functional Assessment Staging \[[@CR23]\] between 6a and 6b at screening). The majority of participants were of Hispanic origin (placebo 69.6 %, memantine 68.3 %).Fig. 1Study flow. \*One patient with a protocol violation was excluded prior to receiving study medication and was not included in the safety population. *ChEI* cholinesterase inhibitor, *ER* extended-release formulation (28 mg), *ITT* intent-to-treat populationTable 1Summary of baseline patient characteristics (safety population)ParameterPlacebo (*n* = 335)Memantine ER (*n* = 341)Age, years^a^76.8 ± 7.876.2 ± 8.4Women, *n* (%)243 (72.5)244 (71.6)White, *n* (%)312 (93.1)324 (95.0)Hispanic, *n* (%)233 (69.6)233 (68.3)Weight, kg^a^64.7 ± 13.365.1 ± 12.8Education, years^a^8.9 ± 4.58.8 ± 4.5MMSE score^a^10.6 ± 2.910.9 ± 2.9MMSE range3--153--17mHIS (at screening)^a^1.1 ± 0.981.1 ± 0.92FAST score (at screening)^a,b^1.3 ± 2.21.2 ± 2.1Concomitant ChEI treatment at baseline Donepezil  Patients, *n* (%)228 (68.1)236 (69.2)  Treatment duration, months^a^17.5 ± 18.416.9 ± 18.3  Mean dose, mg/day^a^7.8 ± 2.68.0 ± 2.8 Galantamine  Patients, *n* (%)68 (20.3)72 (21.1)  Treatment duration, months^a^14.2 ± 12.216.1 ± 18.2  Mean dose, mg/day^a^13.5 ± 5.413.5 ± 5.7 Rivastigmine  Patients, *n* (%)41 (12.2)32 (9.4)  Treatment duration, months^a^16.8 ± 18.817.4 ± 16.9  Mean dose, mg/day^a^6.8 ± 2.96.8 ± 2.6^a^Mean ± standard deviation^b^FAST was administered at screening only; stages 1, 2, 3, ... 7f were assigned numerical values of −4, −3, −2, ... 11*ChEI* cholinesterase inhibitor, *ER* extended-release formulation (28 mg), *FAST* Functional Assessment Staging, *MMSE* Mini-Mental State Examination, *mHIS* modified Hachinski Ischemia Score

Co-primary Efficacy Parameters {#Sec8}
------------------------------

At week 24, the extended-release memantine group significantly outperformed the placebo group on both the SIB (Fig. [2](#Fig2){ref-type="fig"}a; Table [2](#Tab2){ref-type="table"}) and the CIBIC-Plus (Fig. [2](#Fig2){ref-type="fig"}b; Table [2](#Tab2){ref-type="table"}). In addition, the memantine group significantly outperformed the placebo group at week 12 on the SIB (OC) and CIBIC-Plus (OC, LOCF) and at week 18 on the SIB (OC, LOCF) (OC data presented in Fig. [2](#Fig2){ref-type="fig"}a, b).Fig. 2Efficacy outcomes. In ChEI-treated patients with moderate to severe AD, treatment with memantine ER provided significant benefits on primary measures of cognition \[(**a**) SIB\] and global status \[(**b**) CIBIC-Plus\], as well as secondary measures of behavior \[(**d**) NPI\] and verbal fluency (**e**). No statistically significant differences were observed on the measure of function \[(**c**) ADCS--ADL~19~\]. *AD* Alzheimer's disease, *ADCS--ADL* ~*19*~ 19-item Alzheimer's Disease Cooperative Study--Activities of Daily Living, *ChEI* cholinesterase inhibitor, *CIBIC-Plus* Clinician's Interview-Based Impression of Change Plus Caregiver Input, *ER* extended-release formulation (28 mg), *LOCF* last observation carried forward, *LS* least squares, *MMRM* mixed-effects model for repeated measures, *NPI* Neuropsychiatric Inventory, *OC* observed cases, *SEM* standard error of the mean, *SIB* Severe Impairment Battery. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; *p*-values indicating statistically significant differences between groups are shown in bold typeTable 2Mean efficacy assessments at baseline and endpoint (week 24, LOCF; ITT population)Outcome measure*N*Baseline^a^Endpoint change from baseline^a^LSMD \[95 % CI\]*p-*ValueSIB Memantine ER33276.8 ± 17.52.7 ± 11.22.6 \[1.0, 4.2\]0.001 Placebo32775.2 ± 19.30.3 ± 11.5CIBIC-Plus^b^ Memantine ER3334.5 ± 0.873.8 ± 1.2^b^N/A0.008 Placebo3284.5 ± 0.824.1 ± 1.2^b^ADCS--ADL~19~ Memantine ER33133.1 ± 11.1−0.7 ± 6.90.7 \[−0.3, 1.8\]0.177 Placebo32832.8 ± 11.0−1.3 ± 7.7NPI Memantine ER31817.2 ± 15.6−4.3 ± 14.6−2.7 \[−4.5, −0.8\]0.005 Placebo32116.5 ± 15.4−1.6 ± 12.7VFT Memantine ER3305.8 ± 3.80.3 ± 2.80.5 \[0.2, 0.9\]0.004 Placebo3265.7 ± 3.7−0.3 ± 2.5^a^Mean ± standard deviation^b^CIBIC-Plus is a categorical measure of change. Values shown for baseline are the Clinician's Interview-Based Impression of Severity; endpoint values are final CIBIC-Plus scores. *p*-Value is from a Cochran--Mantel--Haenszel test*ADCS--ADL* ~*19*~ 19-item Alzheimer's Disease Cooperative Study--Activities of Daily Living, *CI* confidence interval, *CIBIC-Plus* Clinician's Interview-Based Impression of Change Plus Caregiver Input, *ER* extended-release formulation (28 mg), *ITT* intent-to-treat, *LOCF* last observation carried forward, *LSMD* least squares mean difference, *N/A* not applicable, *NPI* Neuropsychiatric Inventory, *SIB* Severe Impairment Battery, *VFT* verbal fluency test

Secondary and Additional Efficacy Assessments {#Sec9}
---------------------------------------------

At week 24, there were no significant differences between the treatment groups on the ADCS--ADL~19~ (Fig. [2](#Fig2){ref-type="fig"}c; Table [2](#Tab2){ref-type="table"}), but the extended-release memantine group significantly outperformed the placebo group on the NPI (Fig. [2](#Fig2){ref-type="fig"}d; Table [2](#Tab2){ref-type="table"}) and on the VFT (Fig. [2](#Fig2){ref-type="fig"}e; Table [2](#Tab2){ref-type="table"}). In addition, for both the NPI and the VFT, memantine was associated with significant benefits over placebo at weeks 12 and 18 (OC data presented in Fig. [2](#Fig2){ref-type="fig"}d, e).

Safety and Tolerability {#Sec10}
-----------------------

A total of 21/335 patients (6.3 %) in the placebo group and 34/341 patients (9.9 %) in the extended-release memantine group discontinued the trial because of an adverse event (Fig. [1](#Fig1){ref-type="fig"}). The most frequent reasons for discontinuation due to an adverse event were dizziness \[placebo 0 (0 %), memantine 5 (1.5 %)\] and agitation \[placebo 1 (0.3 %), memantine 3 (0.9 %)\]. A total of 214 placebo-treated (63.9 %) and 214 memantine-treated patients (62.8 %) reported treatment-emergent adverse events, with both groups reporting, in general, a similar adverse-event profile (Table [3](#Tab3){ref-type="table"}).Table 3Treatment-emergent adverse events (safety population)Adverse eventPlacebo (*n* = 335)Memantine ER (*n* = 341)Any TEAE214 (63.9)214 (62.8)Fall26 (7.8)19 (5.6)Urinary tract infection24 (7.2)19 (5.6)Headache17 (5.1)19 (5.6)Diarrhea13 (3.9)17 (5.0)Dizziness5 (1.5)**16 (4.7)**Influenza9 (2.7)15 (4.4)Insomnia16 (4.8)14 (4.1)Agitation15 (4.5)14 (4.1)Hypertension8 (2.4)13 (3.8)Anxiety9 (2.7)12 (3.5)Depression5 (1.5)**11 (3.2)**Weight increased3 (0.9)**11 (3.2)**Constipation4 (1.2)**10 (2.9)**Somnolence4 (1.2)**10 (2.9)**Back pain2 (0.6)**9 (2.6)**Aggression5 (1.5)8 (2.3)Hypotension5 (1.5)7 (2.1)Vomiting4 (1.2)7 (2.1)Abdominal pain2 (0.6)**7 (2.1)**Nasopharyngitis10 (3.0)6 (1.8)Confusional state7 (2.1)6 (1.8)Weight decreased**11 (3.3)**5 (1.5)Nausea7 (2.1)5 (1.5)Irritability**8 (2.4)**4 (1.2)Cough**8 (2.4)**3 (0.9)Data \[*n* (%)\] include all adverse events experienced by at least 2.0 % of patients in either group (safety population). Adverse events that were experienced at twice or more the rate in one group compared with the other are indicated by bold type*ER* extended-release formulation (28 mg), *TEAE* treatment-emergent adverse event

Serious adverse events were experienced by 21 placebo-treated (6.3 %) and 28 memantine-treated patients (8.2 %), with fall \[placebo 5 (1.5 %), memantine 2 (0.6 %)\] and urinary tract infection \[placebo 3 (0.9 %), memantine 2 (0.6 %)\] being the most frequent. Pneumonia, cerebrovascular accident, and syncope were the only other serious adverse events experienced by more than one patient in the memantine-treated group \[placebo 0, memantine 2 (0.6 %), for each\]. Nine patients out of 676 died during the trial: 5 (1.5 %) in the placebo group and 4 (1.2 %) in the memantine group. No death was judged to be related or possibly related to treatment in the memantine-treated group.

A greater than twofold difference in the rate of potentially clinically significant (PCS) laboratory values was observed for low hemoglobin \[placebo 3 (1.1 %), memantine 7 (2.4 %)\] and high eosinophil levels \[placebo 4 (1.4 %), memantine 1 (0.3 %)\]; the rates of other PCS laboratory values were similar between the treatment groups.

Discussion {#Sec11}
==========

This study, similar in design to three previous memantine trials in moderate to severe AD \[[@CR8], [@CR9], [@CR24]\], including a trial in patients on stable cholinesterase inhibitor therapy (donepezil) \[[@CR9]\], demonstrated a significant advantage of extended-release memantine (28 mg) over placebo on multiple outcome measures. Patients treated with extended-release memantine performed significantly better than placebo-treated patients on the co-primary outcome measures of cognition and global clinical status, as well as on the measures of behavior and verbal fluency. In contrast to two of the previous studies in patients with moderate to severe AD \[[@CR8], [@CR9]\], no significant difference between treatment groups was observed on the ADCS--ADL~19~. In the current study, patients in both groups remained stable or demonstrated a slight decline after 24 weeks, whereas in the other two studies, placebo-treated patients declined by an average of 5.9 points \[[@CR8]\] and 3.3 points \[[@CR9]\], respectively (OC analyses). In the other previous trial, which investigated memantine monotherapy, placebo-treated patients declined by an average of 2.3 points, and no differences between groups were observed \[[@CR24]\].

It should be noted that our study consisted of a large, mostly non-US Hispanic population (69 %), which has not been extensively represented in clinical trials in AD \[[@CR13]\]. Although other ADL measures have been successfully validated in Hispanic patients \[[@CR25]--[@CR27]\], to our knowledge the only Spanish validation of the ADCS--ADL scale involves the 23-item instrument in Spanish-speaking Americans \[[@CR28]\], and the possibility exists that some items from the 19-item scale may be less applicable to patients with moderate to severe AD from Central or South America.

Also, we find it noteworthy that extended-release memantine treatment demonstrated significant benefits on behavioral symptoms (NPI), in spite of a robust placebo response (Fig. [2](#Fig2){ref-type="fig"}d). A protocol-specified analysis of individual NPI items (not reported here) showed a significant advantage for memantine over placebo on agitation/aggression, irritability/lability, nighttime behavior, and delusions, which is consistent with previous studies \[[@CR10], [@CR29]--[@CR31]\]. Since behavioral symptoms are associated with increased severity of dementia, functional decline, probability of institutionalization, patient care costs, and caregiver burden \[[@CR32]--[@CR34]\], an improvement in their management should translate into a tangible, clinically important benefit.

Memantine treatment in this trial was also associated with significant improvements in semantic fluency \[[@CR22]\]. The semantic fluency task requires attention, information retrieval, and intact semantic associations \[[@CR35]--[@CR37]\], and is strongly dependent upon the hippocampus and related structures in the left mediotemporal lobe \[[@CR38], [@CR39]\]. In patients with AD, semantic fluency positively correlates with measures of memory \[[@CR40]\] and the ability to perform everyday activities \[[@CR35]\].

This study was unique for a number of reasons. First, we examined the efficacy of a higher-dose, extended-release formulation of memantine. Although the currently approved immediate-release formulation in principle has a sufficient half-life to enable once-daily dosing (60--80 h) \[[@CR12], [@CR41]\], the extended-release formulation allows for a higher target dose \[48 % higher steady-state maximum plasma concentration (C~max~) and 33 % higher area under the plasma concentration--time curve from time 0 to 24 h (AUC~0--24~), compared with twice-daily 10-mg dosing of immediate-release memantine; data on file, Forest Research Institute\] and provides a slow release, which could contribute to reducing the rate and severity of adverse reactions resulting from rapid drug absorption. Patients in the extended-release memantine group experienced very few adverse events (Table [3](#Tab3){ref-type="table"}), which were consistent but generally lower in frequency compared with those seen in similar, previous studies of immediate-release memantine in patients with moderate to severe AD \[[@CR8], [@CR9], [@CR11], [@CR12], [@CR24]\]; however, a different study design would be required to properly assess differences between the two formulations. Secondly, this trial allowed concomitant treatment with any of the three currently approved cholinesterase inhibitors; in the only other randomized trial of memantine in patients with moderate to severe AD taking cholinesterase inhibitors, all patients were taking donepezil \[[@CR9]\]. The inclusion of a measure of verbal fluency is also unique; to our knowledge, only one other placebo-controlled trial of an approved anti-dementia drug has used verbal fluency as an outcome measure in patients with AD. In that study, donepezil did not improve phonemic fluency in patients with mild-to-moderate dementia \[[@CR42]\]. Finally, this study was performed in a population that was predominantly Hispanic, a population that has traditionally been under-represented in trials of anti-dementia drugs \[[@CR13]\].

A notable limitation of this study was the absence of an active control arm containing patients treated with standard, immediate-release memantine. Consequently, the new 28-mg extended-release formulation cannot be directly compared with standard dosing in terms of efficacy, adverse events, or adherence to drug. In addition, in order to limit the confounding effects of multiple comorbidities and the exposure of frail individuals to an inactive placebo treatment, this study recruited outpatients who met a set of entry criteria comparable to those typically found in clinical trials of anti-dementia therapies, but which may not be fully representative of an actual out-of-trial population. We recommend that each of these parameters be addressed in future trials. Furthermore, a number of post hoc analyses could provide interesting and useful information, including comparisons between Hispanic and non-Hispanic patients and analyses by the type of cholinesterase inhibitor used. The primary statistical analysis in this study utilized the LOCF approach (an FDA standard at the time of the trial), in which imputation of missing scores is performed using the most recent available values. Since this approach has the potential to create a bias when used in trials of conditions associated with steady clinical decline, such as AD \[[@CR43]\], supportive analyses using OC and MMRM were also performed, and showed nearly identical results (Fig. [2](#Fig2){ref-type="fig"}).

Conclusion {#Sec12}
==========

This trial of a novel, 28-mg, extended-release memantine formulation supports the existing body of evidence that indicates memantine provides cognitive, global, and behavioral benefits in patients with moderate to severe AD treated with a cholinesterase inhibitor, while the new formulation allows for an increased daily dose and simplified delivery regimen. Studies that directly compare the new extended-release formulation with standard dosing should be conducted to further assess efficacy, drug adherence, and caregiver burden.
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